Information  X 
Enter a valid email address

Summit Corporation PLC (SUMM)

  Print      Mail a friend

Tuesday 15 April, 2008

Summit Corporation PLC

Positive results from Phase I clinical trial in...





Summit Corporation plc
("Summit plc" or "the Company")

POSITIVE RESULTS FROM PHASE I CLINICAL TRIAL OF SMT D002 FOR THE
TREATMENT OF SEBORRHOEA, A PRIMARY CAUSE OF ACNE


  * SMT D002 suppresses sebum levels by 90% in repeat-dose trial
  * Results confirm potential of SMT D002 as a novel treatment for
    acne

Oxford, UK, 15 April 2008 - Summit Corporation plc (AIM: SUMM), a
leading UK biotechnology company, today announces a positive outcome
from its repeat-dose Phase I clinical trial of SMT D002, its
candidate for the treatment of seborrhoea (excessive sebum
production), a primary cause of acne.

The study was conducted in 18 healthy volunteers and examined the
effect of repeat oral doses of SMT D002 over a four-day period.  The
key findings of the Phase I clinical trial are:


  * Statistically significant levels of sebum suppression (primary
    endpoint) of 90% when compared to the placebo group (p=0.04)
  * SMT D002 proved to be safe with no serious or unexpected adverse
    side-effects reported
  * Sebum levels measured over six hours following treatment using a
    Sebumeter, an industry accepted method
  * Results from trial support a previous positive Phase I
    single-dose study conducted in nine volunteers

The results of this trial confirm the potential of SMT D002 as a new
therapeutic agent for the treatment of seborrhoea in acne patients.
Acne is a multi-billion dollar market and it is estimated that there
are 54 million patients in the developed world with acne.
Approximately eight million acne sufferers are also resistant to
current topical retinoid acne treatments and therefore any new and
effective treatment is anticipated to gain a sizeable share of this
high-value market.   In addition, seborrhoea is a non-motor symptom
of Parkinson's disease that is estimated to affect a large proportion
of patients.

Summit plans to develop a topical formulation of SMT D002 to further
evaluate its efficacy in the treatment of acne and the Company is
actively seeking a commercial partner to advance this candidate from
the clinic through to the market.

SMT D002 has been developed using Summit's drug reprofiling expertise
whereby the Company identifies and seeks to establish new therapeutic
uses for existing marketed drugs with a long history of safe use.

Richard Storer, DPhil, Chief Scientific Officer of Summit commented:
"The positive outcome of this Phase I clinical trial represents a
major advancement of SMT D002 towards becoming a novel treatment for
seborrhoea in acne and other indications including Parkinson's
disease.   The study showed clinically significant levels of sebum
suppression and confirmed the positive data from an earlier clinical
study. We believe that these clinical data significantly enhance the
value of the SMT D002 programme and make it a very attractive
partnering opportunity for development towards the market."

                              - ENDS -

For more information, please contact:


Summit plc                                   Tel: +44 (0)1235 443951
Steven Lee, PhD, Chief Executive Officer
Darren Millington, ACMA, Chief Financial
Officer
Richard Pye, PhD, Investor Relations

Citigate Dewe Rogerson                       Tel: +44 (0)207 638 9571
Mark Swallow, PhD / Sylvie Berrebi / David
Dible

Panmure Gordon                               Tel: +44 (0)207 459 3600
Andrew Burnett / Rakesh Sharma (Corporate
Finance)
Ashton Clanfield (Corporate Broking)


About Summit plc
Summit plc is a leading UK biotechnology company that discovers and
develops proprietary new drugs. The Company's internal drug
development programmes are underpinned by its advanced carbohydrate
chemistry and zebrafish drug screening technology platforms, which it
also provides on a collaborative or fee-for-service basis to the
pharmaceutical industry.

Summit plc has a broad range of drug discovery programmes in the
clinical, pre-clinical and discovery stages of development, which
target serious diseases with a high unmet medical need. These
therapeutic areas include neurological disorders, anti-infectives,
ophthalmic diseases and oncology.

Summit plc's in-house drug development capabilities combine
world-class expertise in both carbohydrate chemistry with
high-volume, high-content screening using its proprietary zebrafish
technologies. These whole organism screens have the potential to
dramatically decrease the time and cost of drug discovery and
development by delivering data that are highly predictive of the
efficacy and toxicity of potential drug compounds in humans.

The company listed on the AIM market of the London Stock Exchange in
October 2004 - symbol: SUMM

Further information about the company is available at
www.summitplc.com

---END OF MESSAGE---